Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis

BACKGROUND: Risks and benefits of protease inhibitor (PI) (telaprevir or boceprevir) triple therapy in hepatitis C virus (HCV)-infected patients with mildly decompensated cirrhosis, including those wait-listed for liver transplantation (LT), are incompletely known. AIM: To assess virological respons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Aliment Pharmacol Ther
Autors principals: Saxena, V., Manos, M. M., Yee, H. S., Catalli, L., Wayne, E., Murphy, R. C., Shvachko, V. A., Pauly, M. P., Chua, J., Monto, A., Terrault, N. A.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4385588/
https://ncbi.nlm.nih.gov/pubmed/24654657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12718
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars